Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem-Glenbrook Hospital
mi
from
Glenview, IL
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem-Glenbrook Hospital
mi
from
Glenview, IL
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Denver, CO
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
Royal Prince Alfred Hospital
mi
from
Camperdown,
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of California - Irvine Medical Center
mi
from
Irvine, CA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of California - Irvine Medical Center
mi
from
Irvine, CA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of California, Los Angeles (UCLA) - Institute of Urologic Oncology
mi
from
Los Angeles, CA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of California, Los Angeles (UCLA) - Institute of Urologic Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Aurora, CO
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Loyola University Chicago
mi
from
Chicago, IL
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Loyola University Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center Hackensack UMC
mi
from
Hackensack, NJ
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center Hackensack UMC
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
North Shore LIJ Center for Advance Medicine
mi
from
Lake Success, NY
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
North Shore LIJ Center for Advance Medicine
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mem Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mem Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
NYU Cancer Institute
mi
from
New York, NY
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Levin Cancer Institute
mi
from
Charlotte, NC
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Levin Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Saint Luke's University Health Network
mi
from
Bethlehem, PA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Saint Luke's University Health Network
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh, Hillman Cancer Center
mi
from
Pittsburgh, PA
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh, Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - South Austin
mi
from
Austin, TX
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - South Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - El Paso Cancer Treatment Center Grandview
mi
from
El Paso, TX
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - El Paso Cancer Treatment Center Grandview
mi
from
El Paso, TX
Click here to add this to my saved trials
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials